lung cancer
Conditions
Interventions
1:Lobaplatin + etoposide
2:cisplatin + etoposide
Sponsors
Department of pulmonary medicine, The Third Clinical Medical College of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
36 Years to 77 Years
Inclusion criteria
Inclusion criteria: Patients had extensive SCLC, 46 with initial diagnosis by cytology and/or pathological histology with an expected lifetime > 3 months. Systemic assessment was routine blood, urine, and stool tests, liver and kidney function, electrolytes, blood coagulation series, electrocardiogram, chest CT (Computed Tomography), MRI (cranial magnetic resonance imaging), bone ECT (Emission Computed Tomography), neck or abdominal ultrasound systemic PET - CT (position-emission tomography Computed Tomography) check, diagnosis phase of extensive SCLC (using American Veterans Association lung cancer staging), chest CT to evaluate lesions, and PS score not in accord with chemotherapy indications and contraindications.
Exclusion criteria
Exclusion criteria: (1) other serious disease or metabolic autoimmune disease; (2) severe functional disorders such as heart, liver, or kidney failure or fungal infections, severe bleeding tendency, granulocytopenia, or thrombocytopenia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| leukocyte;CEA; | — |
Countries
China
Contacts
Public ContactZhou xin
The Affiliated Cancer Hospital of Xinjiang Medical University
Outcome results
None listed